Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: A case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly

Medical Oncology

Volumn 26, Issue 1, 2009, Pages 62-66

  Taslipinar, A ^a   Bolu, E ^a   Kebapcilar, L ^a   Sahin, M ^a   Uckaya, G ^a   Kutlu, M ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acromegaly; Growth hormone; IGF I; Non Hodgkin's lymphoma; Thyroid cancer

Indexed keywords

CABERGOLINE; CYCLOPHOSPHAMIDE; GROWTH HORMONE; IODINE 131; LEVOTHYROXINE; OCTREOTIDE; PEGVISOMANT; PREDNISONE; SOMATOMEDIN C; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; COP PROTOCOL 2; DRUG DERIVATIVE; ERGOLINE DERIVATIVE; HUMAN GROWTH HORMONE; THYROXINE;

ACROMEGALY; AGED; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPY; FOLLOW UP; GLUCOSE TOLERANCE TEST; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPH NODE BIOPSY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID ADENOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TRANSSPHENOIDAL SURGERY; ULTRASOUND; ADENOMA; METABOLISM; MULTIPLE CANCER; SECRETION; THYROID TUMOR;

ACROMEGALY; ADENOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ERGOLINES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS, MULTIPLE PRIMARY; OCTREOTIDE; PREDNISONE; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; VINCRISTINE;

EID: 65549099785     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9084-9     Document Type: Article

References (37)

1. J Barzilay GJ Heatley GW Cushing 1991 Benign and malignant tumors in patients with acromegaly Arch Intern Med 151 1629 32 10.1001/archinte.151.8.1629
2. PJ Jenkins M Besser 2001 Clinical perspective: acromegaly and cancer: a problem J Clin Endocrinol Metab 86 2935 41 10.1210/jc.86.7.2935 (Pubitemid 32673444)
3. M Prisco G Romano F Peruzzi P Valentinis R Baserga 1999 Insulin and IGF-I receptors signaling in protection from apoptosis Horm Metab Res 31 80 9
4. G Siegel Y Tomer 2005 Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature Endocr Res 31 51 8 10.1080/07435800500229177 (Pubitemid 41419984)
5. RH Alves M Vaisman RR Brasil MR Gadelha 1998 Acromegaly and non-Hodgkin's lymphoma Endocr Pract 4 279 81
6. V Busygina AE Bale 2006 Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis Yale J Biol Med 79 105 14
7. JV Hennessey IM Jackson 1995 Clinical features and differential diagnosis of pituitary tumours with emphasis on acromegaly Baillieres Clin Endocrinol Metab 9 271 314 10.1016/S0950-351X(95)80338-6
8. RA Cordero AL Barkan 2008 Current diagnosis of acromegaly Rev Endocr Metab Disord 9 13 9 10.1007/s11154-007-9060-2
9. AACE Acromegaly Guidelines Task Force 2004 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly Endocr Pract 10 213 25
10. S Ezzat S Melmed 1991 Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 72 245 9
11. S Loeper S Ezzat 2008 Acromegaly: re-thinking the cancer risk Rev Endocr Metab Disord 9 41 58 10.1007/s11154-007-9063-z
12. AD Wright DM Hill C Lowy TR Fraser 1970 Mortality in acromegaly Q J Med 39 1 16
13. BA Bengtsson S Eden I Ernest A Oden B Sjogren 1988 Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984 Acta Med Scand 223 327 35
14. J Etxabe P Gaztambide P Latorre JA Vazquez 1993 Acromegaly: an epidemiological study J Endocrinol Invest 16 181 7
15. C Rajasoorya IM Holdaway P Wrightson DJ Scott HK Ibbertson 1994 Determinants of clinical outcome and survival in acromegaly Clin Endocrinol (Oxf) 41 95 102 10.1111/j.1365-2265.1994.tb03789.x
16. B Swearingen 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly J Clin Endocrinol Metab 83 3419 26 10.1210/jc.83.10.3419 (Pubitemid 28500866)
17. SM Orme RJ McNally RA Cartwright PE Belchetz 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group J Clin Endocrinol Metab 83 2730 4 10.1210/jc.83.8.2730 (Pubitemid 28493768)
18. C Beauregard U Truong J Hardy O Serri 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly Clin Endocrinol (Oxf) 58 86 91 10.1046/j.1365-2265.2003.01679.x (Pubitemid 36098853)
19. IM Holdaway RC Rajasoorya GD Gamble 2004 Factors influencing mortality in acromegaly J Clin Endocrinol Metab 89 667 74 10.1210/jc.2003-031199 (Pubitemid 38269875)
20. M Kurimoto I Fukuda N Hizuka K Takano 2008 The prevalence of benign and malignant tumors in patients with acromegaly at a single institute Endocr J 55 67 71 10.1507/endocrj.K07E-010
21. K Kasagi 1999 Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland Thyroid 9 791 6
22. S Cannavò 2000 Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up Horm Metab Res 32 190 5
23. M Gasperi 2002 Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study J Endocrinol Invest 25 240 5
24. P Tita 2005 High prevalence of differentiated thyroid carcinoma in acromegaly Clin Endocrinol (Oxf) 63 161 7 10.1111/j.1365-2265.2005.02316.x (Pubitemid 41097984)
25. A Cats 1996 Increased epithelial cell proliferation in the colon of patients with acromegaly Cancer Res 56 523 6
26. PJ Jenkins 2000 Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly J Clin Endocrinol Metab 85 3218 21 10.1210/jc.85.9.3218
27. N Onoda 1992 Autocrine role of insulin-like growth factor (IGF)-I in a human thyroid cancer cell line Eur J Cancer 28A 1904 9 10.1016/0959-8049(92) 90033-X
28. P Roger M Taton J Van Sande JE Dumont 1988 Mitogenic effects of thyrotropin and adenosine 3?,5?-monophosphate in differentiated normal human thyroid cells in vitro J Clin Endocrinol Metab 66 1158 65
29. F Minuto 1989 Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue J Clin Endocrinol Metab 68 621 6
30. A Wolk 2004 The growth hormone and insulin-like growth factor I axis, and cancer Lancet 363 1336 7 10.1016/S0140-6736(04)16081-9 (Pubitemid 38529867)
31. D Selvarajah J Webster R Ross J Newell-Price 2005 Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly Eur J Endocrinol 152 569 74 10.1530/eje.1.01888 (Pubitemid 40575802)
32. P Marzullo 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients Pituitary 1 115 20 10.1023/A:1009932521242
33. A Colao 2007 Pegvisomant in acromegaly: why, when, how J Endocrinol Invest 30 693 9
34. X Wang DM Stocco 2005 The decline in testosterone biosynthesis during male aging: a consequence of multiple alterations Mol Cell Endocrinol 238 1 7 10.1016/j.mce.2005.04.009 (Pubitemid 40799577)
35. JS Tenover 2003 Declining testicular function in aging men Int J Impot Res 15 3 8 10.1038/sj.ijir.3901029
36. DW Leung 1987 Growth hormone receptor and serum binding protein: purification, cloning and expression Nature 330 537 43 10.1038/330537a0 (Pubitemid 17164350)
37. H Wu R Devi WB Malarkey 1996 Localization of growth hormone messenger ribonucleic acid in the human immune system-a Clinical Research Center study J Clin Endocrinol Metab 81 1278 82 10.1210/jc.81.3.1278 (Pubitemid 26084004)